

HELSINN HEALTHCARE PRESENTS NEW DATA ON ORIGINAL NIMESULIDE AT THE WORLD INSTITUTE OF PAIN (WIP) CONGRESS (BUDAPEST, 25 SEPTEMBER, 2007)



LUGANO, SWITZERLAND, October 18th, 2007– Helsinn Healthcare wanted this presence at the 4th World Congress of the World Institute of Pain, held in Budapest from 25-28 September 2007, to further confirm the commitment and efforts it has made to bring new evidences regarding Nimesulide's management in the treatment of acute pain.

The congress, one of the most important in its field, saw the participation of approximately 2'000 doctors from over 70 countries.

Among the scientific activities hosted during the congress, Helsinn organised a satellite symposium entirely dedicated to Nimesulide, entitled: *"Achieving effective pain management"*.

The symposium was the perfect occasion to emphasize once again, in the light of all the therapies currently available, the importance of Nimesulide in the symptomatic treatment of acute pain and to present for the first time the


final results of a study in post surgery dental pain:

"Observational prospective survey on the prescriptions of NSAIDs to patients undergoing third molar surgery" (A. Lörincz)

and in addition a preliminary analysis of the results of a trial in the treatment of migraine:

"Efficacy and tolerability of nimesulide for the treatment of migraine attacks: a randomized, multi-country, double-blind, placebo-controlled, cross-over trial" (G. Sandrini), which both will be object of a publication.

Herebelow is the scientific programme of the event:



Helsinn Healthcare Satellite Symposium

"Achieving Effective Pain Management"

Official Satellite Symposium of the 4th World Institute of Pain Congress

Chairpersons

Hans G. Kress
Department of
Anaesthesiology and Pain Therapy,
Medical University,
Vienna, Austria

Giustino Varrassi
Department of Anaesthesiology, University
of L'Aquila,
L'Aquila, Italy

Scientific programme

Hans G. Kress
Department of Anaesthesiology and Pain Therapy,
Medical University, Vienna, Austria
PAIN MECHANISMS AND THE ROLE OF NSAIDS

Giorgio Sandrini
IRCCS Institute of Neurology C. Mondino Foundation,
University of Pavia, Pavia, Italy
OVERVIEW OF THE ANALGESIC ACTION OF NIMESULIDE

Adam Lörcincz
Department of Oral and Maxillofacial Surgery,
Sемmelweis University, Budapest, Hungary
NIMESULIDE AND POST-OPERATIVE DENTAL PAIN: FINAL RESULTS
OF AN OBSERVATIONAL STUDY



It is also important to underline how, at the opening and closing of the session, the two the two chairmen (H.G. Kress, G. Varrassi), had the opportunity to emphasise, to both the doctors and partners who attended the symposium, that the conclusion of the CHMP/EMA evaluation confirmed Nimesulide's positive benefit/risk profile.



Helsinn's presence in this congress with a satellite symposium entirely based around Nimesulide, is additional confirmation of how the product, after 22 years of commercialization, is still able to offer new clinical evidence in different fields characterised by acute pain.

About NIMESULIDE

NIMESULIDE is one of the most used non-steroidal anti-inflammatory drugs in the EU. Present on the market since 1985, nimesulide-containing products are currently available in approximately 50 countries. To date, 500 million courses of treatment have been made in 22 years of marketing.

About HELSINN HEALTHCARE

HELINN HEALTHCARE SA, a privately owned pharmaceutical group with headquarters in Switzerland, is the worldwide licensor of nimesulide. HELINN's core business is the licensing of pharmaceuticals in various therapeutic niche areas (anti-inflammatory, gastroenterology, oncology and supportive care). The company's business strategy is to in-license early stage new chemical entities and complete their development from the performance of pre-clinical/clinical studies and CMC development to the attainment of market approvals in strategic markets (U.S. and Europe). HELINN's products are eventually out-licensed to its marketing partners for distribution. The active pharmaceutical

ingredients and the finished dosage forms are manufactured at HELSINN's cGMP facilities and supplied worldwide to its customers.

For more information about HELSINN, please visit the company's Web site at www.helsinn.com.

Contact person at HELSINN, Switzerland

Massimo Tosi, M. Chem. Pharm., Senior Manager, Commercial Operations

Tel: +41 (0)91-985-21-14 mto@helsinn.com